MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Ocugen, Inc., (NASDAQ:OCGN)*
Organization & Developments: Ocugen
Parents
Ocugen, Inc., (NASDAQ:OCGN)*
Children
2020: Ocugen Is a Bold Biotech Bet, But the Payoff Could Be Rich
2021: FDA rejects emergency use authorization for Bharat Biotech’s Covaxin jab
2021: Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors
2021: With A COVID EUA Looming, Ocugen Looks Set To Boom Or Bust
2022: Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan_ ocugen
2022: Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course_seekingalpha.com
2022: Ocugen: Still Struggling_ seekingalpha.com
2023: OCUGEN MUCOSAL VACCINE CANDIDATE OCU500 SELECTED BY NIH/NIAID PROJECT NEXTGEN FOR INCLUSION IN CLINICAL TRIALS
2024: Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
2024:Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues
2025: Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial
2026: Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)
Jumps
*Key People: Ocugen
Finance & Acquisitions: Ocugen